KLRK1 and neoplasm: Although NKG2D ligands may not be entirely tumor-specific, their widespread presence in tumors and the tumor microenvironment can effectively activate the NKG2D receptor, which is why we chose NKG2D as a CCR rather than as a direct CAR target.